| Datum | Källa | Rubrik | Typ | Alternativ |
|---|---|---|---|---|
| 2024-06-11 | Nanexa | First patient dosed in Nanexa's Phase I trial of NEX-22 in type 2 diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-06-11 | Nanexa | Första patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-15 | Nanexa | Kommuniké från årsstämma i Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-15 | Nanexa | Bulletin from Nanexa’s Annual General Meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-15 | Nanexa | Nanexa receives approval for NEX-22 clinical study | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-15 | Nanexa | Nanexa erhåller godkännande för klinisk studie med NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-10 | Redeye | Redeye: Nanexa Q1 2024 - Insightful capital markets day | Pressreleaser | Ladda ner | Visa Stäng |
|
Pressreleaser |
Redeye: Nanexa Q1 2024 – Insightful capital markets dayRedeye updates its view of Nanexa following the Q1 report and recent events in the company, including the CMD earlier this week, which offered a deeper look into the company’s several activities. Read more and download the Research Update. |
||||
| 2024-05-10 | Emergers | Emergers: Equity Research | NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-03 | Nanexa | Nanexa publishes interim report for January-March 2024 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-03 | Nanexa | Nanexa publicerar delårsrapport för januari-mars 2024 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-30 | Nanexa | Invitation to comment on Nanexa's Q1 report 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-30 | Nanexa | Inbjudan till kommentar av Nanexas Q1-rapport 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-29 | Nanexa | Nanexa invites to Capital Markets Day on May 7 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-29 | Nanexa | Nanexa bjuder in till kapitalmarknadsdag 7 maj | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-16 | Nanexa | Godkännandet av klinisk prövningsansökan för NEX-22-studien försenas | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-16 | Nanexa | Approval of clinical trial application for NEX-22 study delayed | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-15 | Nanexa | Notice of annual general meeting in Nanexa AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-15 | Nanexa | Kallelse till årsstämma Nanexa AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-27 | Nanexa | Nanexa publicerar årsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-27 | Nanexa | Nanexa publishes annual report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-22 | Redeye | Redeye: Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-22 | Emergers | Emergers: Equity Research | NANEXA: Focus on dual GLP-1 opportunities and the partner projects | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-21 | Nanexa | Nanexa publishes year-end report and Q4 report 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-21 | Nanexa | Nanexa publicerar bokslutskommuniké och Q4-rapport 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-20 | Nanexa | Invitation to presentation of Nanexa's year-end report and Q4 report 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-20 | Nanexa | Inbjudan till presentation av Nanexas bokslutskommuniké och Q4-rapport 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-21 | Emergers | Emergers: Equity Research | NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-20 | Nanexa | Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-20 | Nanexa | Nanexa optimizes business operations through tactical priorities | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-20 | Nanexa | Nanexas kliniska prövningsansökan för NEX-22 fas I-studie emottagen av EMA | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-20 | Nanexa | Nanexa optimerar affärsverksamheten genom taktiska prioriteringar | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-30 | Nanexa | Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-30 | Nanexa | Nanexa byter Certified Adviser till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-29 | Nanexa | Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-29 | Nanexa | Nanexa signs evaluation agreement with a large global pharmaceutical company | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-21 | Redeye | Redeye: Nanexa Q3 - Focused approach | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-21 | Emergers | Emergers: Equity Research | NANEXA: Raising our LOAs following a review of the projects | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-20 | Nanexa | Nanexa publishes interim report for January – September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-20 | Nanexa | Nanexa publicerar delårsrapport för januari-september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-14 | Nanexa | Nanexa presenterade hälsoekonomiska data på internationell kongress | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-14 | Nanexa | Nanexa presented Health Economical data at international conference | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-01 | Emergers | Emergers: Equity Research | NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-30 | Nanexa | Nanexa offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-30 | Nanexa | Nanexa announces outcome of rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-20 | Nanexa | Nanexa erhåller ytterligare teckningsförbindelse i pågående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-20 | Nanexa | Nanexa receives additional subscription undertaking in the ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-11 | Nanexa | Nanexa publishes EU growth prospectus in connection with rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-11 | Nanexa | Nanexa offentliggör EU-tillväxtprospekt med anledning av företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-11 | Nanexa | Nanexa reports preliminary key financial information for the period January-September 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-11 | Nanexa | Nanexa rapporterar preliminär finansiell nyckelinformation för perioden januari-september 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-11 | Emergers | Emergers: Equity Research | NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-05 | Nanexa | Nanexa completes clinical phase I study with NEX-20 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-05 | Nanexa | Nanexa har slutfört den kliniska fas I-studien med NEX-20 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-28 | Nanexa | Nanexa bjuder in till investerarmöte 9 oktober i Uppsala | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-28 | Nanexa | Nanexa invites to investor meeting on October 9th in Uppsala | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-22 | Nanexa | Invitation to commentary regarding rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-22 | Nanexa | Inbjudan till kommentar gällande företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-22 | Emergers | Emergers: NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-21 | Nanexa | Nanexa carries out a rights issue of approximately SEK 121 million | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-21 | Nanexa | Nanexa genomför en företrädesemission om cirka 121 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-06 | Nanexa | Nanexa presenterar vid ISPOR Europe 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-06 | Nanexa | Nanexa presents at ISPOR Europe 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-30 | Nanexa | Nanexa beviljas patent i Indien | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-30 | Nanexa | Nanexa is granted patent in India | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-24 | Redeye | Redeye: Nanexa Q2 - Solid progress but a capital injection is on the horizon | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-24 | Emergers | Emergers: Equity Research | NANEXA: Progress with NEX-20 and NEX-22 Amid Rising GLP-1 Interest | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-23 | Nanexa | Nanexa publicerar delårsrapport för januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-23 | Nanexa | Nanexa publishes interim report for January – June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Nanexa | Invitation to presentation of Nanexa’s Q2 report 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Nanexa | Inbjudan till presentation av Nanexas Q2-rapport 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Nanexa | Nanexa bekräftar fortsatt positiva resultat från en ny preklinisk studie av NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Nanexa | Nanexa confirms continued positive results from a new preclinical study of NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Nanexa | Nanexa obtains pharmacokinetic data from the NEX-20 Phase 1 study confirming controlled release of lenalidomide | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Nanexa | Nanexa erhåller farmakokinetiska data från den kliniska fas I-studien med NEX-20 som konfirmerar kontrollerad frisättning av lenalidomid | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-07-10 | Nanexa | Summer letter from Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-07-10 | Nanexa | Sommarbrev från Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
Kommande händelser